RNA Leaders’ Post

In this symposium, an expert panel will discuss mRNA-based vaccines, current approaches and challenges, and how researchers are moving RNA therapeutics forward in exciting new directions. Save your spot: https://ow.ly/s7ff50SpA2n

The success of linear mRNA vaccines has set the stage for the next generation of RNA modalities. The rise of these innovations demands conversations about what the future RNA therapeutics regulatory paradigm should look like. On May 2 at 11 am EST, join our Chief Quality & Regulatory Officer, Melanie Cerullo M.S., CQA at Advancing RNA Live for a panel discussion exploring: ➤What an “ideal” RNA therapeutics regulatory paradigm could look ➤ Best practices for working with regulators to usher encoding RNA products into the clinic ➤ Approaches for “platforming” product development. Book your spot today 👇 https://lnkd.in/dYEbe5Zb #DrugDevelopment #RNATherapeutics #mRNA

Looking back on the discussions at the RNA Leaders' Congress in Basel. It was great to see many researchers gathering to discuss advances and challenges in #RNA therapeutics and vaccines. Thanks to the speakers for sharing their insights. As one of the panelists mentioned, I'm eager to see how we address global health challenges by tackling these 3Es: Entry to cells Escape from endosomes Efficacy #RNA #Oligonucleotides #Synthesizers #Biotech

There is still time to register for our upcoming rare disease webinar on February 27th! Advances in the understanding of rare disease biology, coupled with innovative technology and therapeutic platforms, have led to progress in the research and development of drugs for rare diseases. Despite these advances, many rare diseases still lack useful treatments and the need for new approaches remains high. In this webinar, we will discuss important trends in rare disease therapeutics and highlight ways of accelerating the drug discovery and development process. Don’t miss your chance to ask questions to our experts! Register Now by Clicking ⬇️ https://lnkd.in/eFDFddVw #RareDiseases #RareDiseaseDay #drugdiscovery #biotech #RareDiseaseDay2024

Join us to discover simple and effective tools for #RNA CQA assessment. Learn how the BioAccord LC-MS System and waters_connect informatics make these analyses accessible to scientists developing RNA therapeutics and vaccines. Register here for Session 1: https://bit.ly/3vab7Pa

Next week, starting on Tuesday 22 October 2024 at 4.00pm (BST) we have a 3 Day Virtual Event - Illuminating New Frontiers-Cracking the Undruggable Code - available free to all those that register at https://bit.ly/3Yq8AMT You can select to watch every day, or just the sessions you want. The sessions last 3 hours. Day One - Rethinking Undruggable Targets: New Insights into RAS and Protein Interactions Day Two - Next-Generation Therapeutics: The Power of Induced Proximity and Targeted Protein Degradation Day Three - Unlocking the Potential of RNA: New Paths for Targeting RNA #ProteinDegradation #CRISPR #RNA

Next week, starting on Tuesday 22 October 2024 at 4.00pm (BST) we have a 3 Day Virtual Event - Illuminating New Frontiers-Cracking the Undruggable Code - available free to all those that register at https://bit.ly/3YqpqLO You can select to watch every day, or just the sessions you want. The sessions last 3 hours. Day One - Rethinking Undruggable Targets: New Insights into RAS and Protein Interactions Day Two - Next-Generation Therapeutics: The Power of Induced Proximity and Targeted Protein Degradation Day Three - Unlocking the Potential of RNA: New Paths for Targeting RNA #ProteinDegradation #CRISPR #RNA

Following eye-watering investments into the next generation RNA space in 2023, the 3rd Next Generation RNA Therapeutics Summit returns this May to help you unlock the enormous therapeutic and commercial potential of this emerging class of modalities. Download the program: https://ter.li/s2uxkg 🌟 Enhance characterization, safety and potency to develop and manufacture effective self-amplifying RNA therapeutics for patients with input from Johnson & Johnson, Replicate Bioscience, Inc. and Strand Therapeutics 🌟 Overcome quality and scalability hurdles to increase clinical success of circular RNAs towards patients in need with input from Orbital Therapeutics and Laronde 🌟 Successfully develop first-in-class next generation RNA therapies with groundbreaking potential to treat “incurable” diseases with insights from noctuRNA Therapeutics, Circio Holding ASA and Pfizer 🌟 Learn from diverse platforms to address shared hurdles, differentiate pipelines and enhance next generation RNA strategies towards regulatory approval with input from John Hopkins University, Rothwell Figg and Capstan Therapeutics See the full list of speakers and their session details: https://ter.li/s2uxkg #RNA #nextgenerationRNA #RNAtherapeutics #circularRNA #circRNA #saRNA #selfamplifyingRNA #eRNA #tRNA #RNASummit #RNAConference

As we celebrate #RNADay today, we want to recognize the scientists and researchers who continue to drive innovation in the RNA field. As a leader in RNA-based therapeutics, we are proud to leverage our proprietary Antibody Oligonucleotide Conjugates (AOC) platform which combines the targeting precision of antibodies with the therapeutic potential of oligonucleotides to advance our clinical development programs for three rare muscle diseases: #DM1, #FSHD, and #DMD. Over the last year, we have shared exciting data across all three clinical programs, reaffirming the potential of our AOC platform to profoundly improve people’s lives. Today we want to recognize and celebrate the important efforts of our #BeAVID team as we work to realize our vision to revolutionize RNA therapeutics and bring treatments to patients as quickly as possible. Learn more about our AOC platform and our work in the RNA field in a recent Drug Development & Delivery article, featuring our Distinguished Scientist and Strategic Leader, Art Levin, PhD. Read the article: https://lnkd.in/eWBrJiAM

Are you involved in cellular immunotherapy development? We want to hear from you! 🔬 We're eager to learn from biotech and pharma experts about current workflows, bottlenecks and pain points in the pre-clinical discovery and validation of cellular immunotherapies. ⚙️ Share your expertise with us by completing or sharing our brief survey via the link below. ⬇️ https://lnkd.in/dT3NF6eZ Visit us at www.avigen.co.uk or reach out to us directly to learn more or share your insights. #CellularImmunotherapy #Biotech #Pharma #ResearchAndDevelopment #Immunotherapy #CART #TCRT #DiscoveryAndValidation